S&P 500
5,961.07
-0.2%
-$9.74
DJI
42,473.24
+0.1%
+$45.50
NASDAQ
19,382.11
-0.4%
-$78.38
Bitcoin
103,043.00
-1.9%
-2,009.05
AAPL
$202.23
-0.3%
-$0.59
AMZN
$209.52
+1.1%
+$2.29
GOOG
$171.02
+1.0%
+$1.63
META
$687.69
-0.0%
-$0.26
MSFT
$469.44
+1.2%
+$5.57
NVDA
$140.46
-1.0%
-$1.46
TSLA
$286.27
-13.8%
-$45.78
iTeos Therapeutics (NASDAQ: ITOS)
$10.11
(-0.9%)
-$0.09
Price as of June 5, 2025, 2:55 p.m. ET
iTeos Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
iTeos Therapeutics Company Info
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
News & Analysis
Featured Article
Why iTeos Therapeutics Topped the Market Today
The stock is about to become a component of a high-profile index.
Eric Volkman | Jan 3, 2022
Featured Article
Why iTeos Therapeutics Stock Soared Today
The biotech struck a potential $2 billion deal with a pharmaceutical giant.
Joe Tenebruso | Jun 14, 2021
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.